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Abstract
Background Critically ill patients with renal insufficiency are
predisposed to both deep vein thrombosis (DVT) and bleeding.
The objective of the present study was to evaluate the
prevalence, incidence and predictors of DVT and the incidence
of bleeding in intensive care unit (ICU) patients with estimated
creatinine clearance <30 ml/min.
Methods In a multicenter, open-label, prospective cohort study
of critically ill patients with severe acute or chronic renal
insufficiency or dialysis receiving subcutaneous dalteparin
5,000 IU once daily, we estimated the prevalence of proximal
DVT by screening compression venous ultrasound of the lower
limbs within 48 hours of ICU admission. DVT incidence was
assessed on twice-weekly ultrasound testing. We estimated the
incidence of major and minor bleeding by daily clinical
assessments. We used Cox proportional hazards regression to
identify independent predictors of both DVT and major bleeding.
Results Of 156 patients with a mean (standard deviation)
creatinine clearance of 18.9 (6.5) ml/min, 18 had DVT or
pulmonary embolism within 48 hours of ICU admission, died or
were discharged before ultrasound testing – leaving 138
evaluable patients who received at least one dose of dalteparin.
The median duration of dalteparin administration was 7 days
(interquartile range, 4 to 12 days). DVT developed in seven
patients (5.1%; 95% confidence interval, 2.5 to 10.1). The only
independent risk factor for DVT was an elevated baseline Acute
Physiology and Chronic Health Evaluation II score (hazard ratio
for 10-point increase, 2.25; 95% confidence interval, 1.03 to
4.91). Major bleeding developed in 10 patients (7.2%; 95%
confidence interval, 4.0 to 12.8), all with trough anti-activated
factor X levels ≤ 0.18 IU/ml. Independent risk factors for major
bleeding were aspirin use (hazard ratio, 6.30; 95% confidence
interval, 1.35 to 29.4) and a high International Normalized Ratio
(hazard ratio for 0.5-unit increase, 1.68; 95% confidence
interval, 1.07 to 2.66).
Conclusion In ICU patients with renal insufficiency, the
incidence of DVT and major bleeding are considerable but
appear related to patient comorbidities rather than to an
inadequate or excessive anticoagulant from thromboprophylaxis
with dalteparin.
Clinical Trial Registration Number NCT00138099.
Anti-Fxa = anti-acitvated factor X; CI = confidence interval; DVT = deep vein thrombosis; ICU = intensive care unit; LMWH = low-molecular-weight 
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Introduction
Approximately 30% of critically ill patients admitted to an inten-
sive care unit (ICU) will have renal insufficiency at the time of
admission or will develop the condition during their ICU stay.
These patients have a fourfold higher risk for developing deep
vein thrombosis (DVT) compared with ICU patients without
renal insufficiency [1-3]. Furthermore, dialysis dependence
prior to ICU admission is an independent risk factor for ICU-
acquired DVT, potentially related to high levels of fibrinogen,
von Willibrand's factor and lipoprotein(a) [4,5], and for treat-
ment with erythropoiesis-stimulating agents [6,7]. Like other
critically ill patients, patients with renal insufficiency face an
increased risk of DVT because they are typically immobile,
undergo invasive procedures, and have large central venous
catheters in place for hemodialysis, ultrafiltration or intensive
monitoring. At the same time, ICU patients with renal insuffi-
ciency are also predisposed to bleeding because of uremic
platelet dysfunction, multiple comorbidities, coagulopathies
and concomitant treatment with antiplatelet or anticoagulant
agents.
Knowledge of the risk factors for, and frequency of, DVT and
bleeding may help clinicians to risk-stratify ICU patients with
renal insufficiency, and may help guide appropriate thrombo-
prophylaxis. Competing risks of thrombosis and bleeding in
these patients poses challenges for thromboprophylaxis. For
example, some authorities urge caution in using low-molecu-
lar-weight heparin (LMWH) in patients with renal insufficiency
[8], and practice guidelines suggest withholding or dose-
adjusting LMWH in patients with severe renal insufficiency
because of a concern that bioaccumulation may result in
bleeding [9]. Most studies of LMWH have systematically
excluded patients with renal insufficiency, and few studies
have assessed the frequency and determinants of both DVT
and bleeding in this challenging high-risk population.
The purpose of the present study was to evaluate the preva-
lence, incidence and predictors of DVT and major bleeding
among critically ill patients with an estimated creatinine clear-
ance <30 ml/min/1.73 m2.
Materials and methods
Study design
We conducted a multicenter, open-label, prospective cohort
study assessing thromboprophylaxis with dalteparin 5,000 IU
once daily until ICU discharge or for a maximum of 30 days in
critically ill ICU patients with severe renal insufficiency, and we
found that dalteparin bioaccumulation did not occur as meas-
ured by twice-weekly trough anti-activated factor X (anti-FXa)
levels [10]. The purpose of the present report is to estimate
the prevalence, incidence and risk factors for venous throm-
boembolism and bleeding in critically ill patients with severe
renal insufficiency.
Patients
We enrolled adult patients older than 18 years of age, with a
body weight >45 kg, with an expected ICU length of stay
exceeding 72 hours and with severe renal insufficiency –
defined by a creatinine clearance less than 30 ml/min/1.73 m2
based on the Cockroft–Gault formula [11] – or with chronic
dialysis. Exclusion criteria were concomitant conditions that
increased the risk for bleeding (that is, active bleeding, platelet
count <75 × 109/l, International Normalized Ratio or activated
partial thromboplastin time >2 times upper limit of normal), a
need for therapeutic anticoagulation, life expectancy <14
days, or receipt of palliative care.
Written informed consent for study participation was provided
by surrogate decision-makers or patients. This study was
approved by the Research Ethics Boards of all participating
sites, which are Canadian university-affiliated hospitals with
closed mixed medical–surgical ICUs (see
Acknowledgements).
Outcome measures
Venous thromboembolism
All patients had bilateral compression lower-limb venous ultra-
sound within 48 hours of study enrolment and twice weekly
thereafter [1] until ICU discharge or 30 days, whichever came
first. A standard technique was used to assess venous seg-
ments in six locations from the trifurcation to the common fem-
oral vein. This technique, which has high inter-rater reliability in
ICU patients [12], was performed by specifically trained study
ultrasound technologists and radiologists. DVT was defined
by a noncompressible vein segment [13], and was classified
as catheter-related if it occurred within 24 hours of placement
of a central venous (including dialysis) catheter in the same
site. Screening for pulmonary embolism was not conducted
routinely; if suspected, pulmonary embolism was diagnosed
by standard clinical and diagnostic criteria [14,15].
Bleeding
All patients underwent daily bedside clinical assessment using
a validated bleeding tool for the ICU population [16]. Bleeding
was defined as major if, in the absence of another cause, the
patient fulfilled one of three definitions: first, a decrease in
hemoglobin by 20 g/l or more in the absence of another cause
along with one of either transfusion of more than 2 units
packed red cells without a corresponding increase in hemo-
globin, a spontaneous decrease in systolic blood pressure by
more than 20 mmHg, or an increase in heart rate of 20 beats/
min; second, objectively confirmed bleeding at a critical site
(for example, retroperitoneal, intracranial); or, finally, bleeding
at a wound site requiring an intervention (for example, reoper-
ation). Bleeding that did not satisfy these criteria was defined
as minor.
If a major bleed preceded death, a distinction was made
between patients dying with bleeding (for example, a patientAvailable online http://ccforum.com/content/12/2/R32
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with renal failure and ongoing melena had a hyperkalemic car-
diac arrest) and patients dying due to bleeding (for example, a
patient dying from hypovolemic shock due to massive uncon-
trolled upper gastrointestinal hemorrhage). Cases fulfilling the
former criteria were classified as major bleeding, while the lat-
ter criteria were considered to represent fatal bleeding.
Anti-activated factor X levels
We measured trough anti-FXa levels twice weekly (Mondays
and Thursdays), 20 hours after the prior dalteparin dose, to
assess for dalteparin bioaccumulation. The anti-FXa level is
approved by laboratory consensus groups to measure the anti-
coagulant effect of LMWHs [17,18].
The first trough anti-FXa level was measured after a patient
had received at least one dose of dalteparin. We also
assessed dalteparin pharmacokinetics by measuring anti-FXa
levels at 0 hours (baseline), 1 hour, 2 hours, 4 hours, 8 hours,
12 hours, 20 hours, and 24 hours after the prior dalteparin
dose on approximately days 3, 10, and 17 after the start of
dalteparin. Pharmacokinetic assessments were used to
assess the adequacy of anticoagulant effect based on peak
anti-FXa levels measured at 2 hours and 4 hours after the prior
dalteparin dose.
Patient management
Patient management was left to the discretion of the ICU team,
which was blinded to anti-FXa levels. Patients receiving inter-
mittent hemodialysis continued dalteparin unless a contraindi-
cation developed. The catheter patency strategy for patients
receiving continuous dialysis was at the discretion of the ICU
team, and included no intervention, therapeutic unfractionated
heparin or citrate. Research coordinators who prospectively
recorded bleeding and DVT outcomes during the study were
also unaware of the anti-FXa levels.
Statistical analysis
For all descriptive analyses, we present categorical data as
counts and percentages, and present continuous data as the
mean (standard deviation) or median (interquartile range) if
data were skewed. The prevalence (at the time of admission to
the ICU) and the incidence (during the ICU stay) of DVT and
pulmonary embolism are expressed as a percentage and the
associated 95% confidence interval (CI). The incidences of
major and minor bleeding were expressed as the percentage
and 95% CI. From the dalteparin pharmacokinetic data, we
present peak anti-FXa levels at 2 hours and 4 hours after drug
administration to assess the adequacy of the anticoagulant
effect of prophylactic doses of dalteparin.
We performed Cox proportional hazards regression analyses
using backwards selection to identify independent risk factors
for major bleeding and venous thromboembolism (proximal
DVT only, since no incident cases of pulmonary embolism
were identified).
In the major bleeding prediction model, the following risk fac-
tors were a priori independent variables: baseline characteris-
tics (age, Acute Physiology and Chronic Health Evaluation II
score [19], surgical versus medical admission, pre-ICU renal
status (acute renal failure, acute on chronic renal failure,
chronic renal failure not dialysis dependent, dialysis depend-
ent)), and time-dependent predictors (type of dialysis in ICU
(continuous or intermittent in preceding 3 days), International
Normalized Ratio, activated partial thromboplastin time, plate-
let count, therapeutic heparin treatment (within preceding 3
days), prophylactic dalteparin (within preceding 3 days),
detectable trough anti-FXa level (within preceding 3 days),
and any dose of aspirin treatment (within preceding 3 days)).
In the DVT prediction model, the foregoing were a priori inde-
pendent variables (except the detectable trough anti-FXa
level) and the following additional risk factors were included:
baseline venous thromboembolism risk factors (personal or
family history, known thrombophilic disorder, current or recent
(in past 5 years) malignancy), and time-dependent predictors
(red blood cell transfusion, fresh-frozen plasma transfusion,
platelet transfusion, central venous catheter, inotrope or vaso-
pressor dependency, and mechanical ventilation (all within
preceding 3 days)).
Results
Patient characteristics and management
We enrolled 156 patients with a mean (standard deviation)
creatinine clearance of 18.9 (6.5) ml/min within 3.9 (1.6) days
of ICU admission. Fifteen patients had prevalent DVT (n = 14)
or pulmonary embolism (n = 1) diagnosed within 48 hours of
study enrolment. These 15 patients with prevalent venous
thromboembolism (9.6%) were excluded from our assessment
of the incidence of DVT and predictors of incident DVT in the
ICU, as were three additional patients because of ICU death
(n = 2) or discharge (n = 1) prior to baseline venous ultra-
sound testing. The baseline characteristics of the 138 patients
who received at least one dose of dalteparin and were
included in the subsequent analyses are presented in Table 1.
In total, 121 (87.7%) patients had at least one central venous
catheter during their ICU stay (61.6% internal jugular, 1.4%
external jugular, 21.0% subclavian, 8.0% brachial and 17.4%
femoral). The median duration of dalteparin thromboprophy-
laxis was 7 days (interquartile range, 4 to 12 days). Dalteparin
was held for at least 1 day in 43 patients for a median of 5 days
(interquartile range, 1 to 10 days) due to bleeding, potential for
bleeding or need for therapeutic anticoagulation. During days
in which patients were bleeding or at risk for bleeding, antiem-
bolic stockings were used for a median of 1 day (interquartile
range, 1 to 3 days) by 29 (21.0%) patients (12.0% knee-
length stockings, 8.0% thigh-length stockings); pneumatic
compression devices were used for a median of 3 days (inter-
quartile range, 1 to 8 days) by 11 (8.0%) patients.Critical Care    Vol 12 No 2    Cook et al.
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Table 1
Characteristics of enrolled patients
Characteristic Value
Age (years), mean (standard deviation) 68.3 (15.5)
Female, n (%) 77 (55.8)
Acute Physiology and Chronic Health Evaluation II score, mean (standard deviation) 27.6 (8.2)
Body mass index (kg/m2)a 30.7 (8.4)
Surgical admission, n (%) 36 (26.1)
Primary admission diagnosis, n (%)
Cardiovascular 15 (10.9)
Pulmonary 33 (23.9)
Gastrointestinal 26 (18.8)
Neurologic 6 (4.3)
Sepsis 31 (22.5)
Metabolic 6 (4.3)
Hematologic 16 (11.6)
Renal 2 (1.4)
Orthopedic 3 (2.2)
Renal classification, n (%)
Acute renal failure 85 (61.6)
Acute on chronic 32 (23.2)
Chronic renal failure 9 (6.5)
Chronic dialysis 12 (8.7)
Creatinine clearance (ml/min/1.73 m2), mean (standard deviation) 18.9 (6.5)
Creatinine clearance, n (%)
<10 ml/min/1.73 m2 or chronic dialysis 13 (9.4)
10 to 14.9 ml/min/1.73 m2 28 (20.3)
15 to 19.9 ml/min/1.73 m2 37 (26.8)
20 to 24.9 ml/min/1.73 m2 31 (22.5)
25 to 30 ml/min/1.73 m2 29 (21.0)
Intensive care unit length of stay (days), median (interquartile range) 9 (5 to 15)
Management during intensive care unit stayb
Never dialyzed 76 (55.1)
Intermittent hemodialysis only 30 (21.7)
Continuous hemodialysis (includes slow low-efficiency dialysis) only 10 (7.2)
Peritoneal dialysis only 3 (2.2)
Intermittent and continuous hemodialysis 17 (12.3)
Intermittent hemodialysis and peritoneal dialysis 1 (0.7)
Continuous hemodialysis and peritoneal dialysis 0 (0)
Intermittent and continuous hemodialysis, and peritoneal dialysis 1 (0.7)
Intensive care unit mortality, n (%) 29 (21.0)
Characteristics of patients enrolled in the DIRECT study, n = 138. aValues unavailable for two patients. bOut of 138 patients included in this study, 
45% required hemodialysis (intermittent or continuous), or peritoneal dialysis, or a combination.Available online http://ccforum.com/content/12/2/R32
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Study outcomes
Venous thromboembolism
Seven patients developed DVT (six lower-limb DVT and one
upper-limb DVT), for an incidence of 5.1% (95% CI, 2.5 to
10.1). Four DVTs were catheter related. No patient was diag-
nosed with pulmonary embolism. DVT occurred despite ade-
quate levels of prophylactic anticoagulation: the median peak
anti-FXa levels 2 hours and 4 hours after dalteparin administra-
tion were 0.29 (interquartile range, 0.19 to 0.39) based on
159 observations in 101 patients, and 0.31 (interquartile
range, 0.22 to 0.43) based on 153 observations in 98
patients, respectively.
These mean peak anti-FXa levels achieved with prophylactic-
dose dalteparin are consistent with peak prophylactic levels of
anticoagulation of 0.20–0.40 IU/ml observed in other hospital-
ized medical and surgical patients, indicating that our prophy-
laxis regimen had adequate bioavailability and an appropriate
anticoagulant effect [20,21].
Bleeding
Ten patients developed major bleeding, and two patients died
with bleeding; the incidence was 7.2% (95% CI, 4.0 to 12.8).
Twenty-four patients developed minor bleeding, for an inci-
dence of 17.4% (95% CI, 12.0 to 24.6).
Predictors of deep vein thrombosis and major bleeding
An increased Acute Physiology and Chronic Health Evaluation
II score (hazard ratio for 10-unit difference, 2.25; 95% CI, 1.03
to 4.91) was a risk factor for DVT, as shown in Table 2. Aspirin
use (hazard ratio, 6.30; 95% CI, 1.35 to 29.4) and an
increased International Normalized Ratio (hazard ratio for 0.5-
unit difference, 1.68; 95% CI, 1.07 to 2.66) were risk factors
for major bleeding, as shown in Table 3.
Discussion
There are two principal findings of this study of thromboproph-
ylaxis with dalteparin 5,000 IU once daily in critically ill patients
with severe renal insufficiency. First, the incidence of DVT and
major bleeding are considerable – at 5% and 7%, respectively
– consistent with outcome rates in other studies involving crit-
ically ill patients receiving different methods of thromboproph-
ylaxis. Second, our assessment of risk factors for DVT and
major bleeding suggests that these outcomes were a conse-
quence of comorbidities. We did not find that an inadequate
anticoagulant effect contributed to DVT, and we did not find
that an excessive anticoagulant effect contributed to major
bleeding.
The 5% incidence of proximal DVT we observed is consistent
with other studies in critically ill patients receiving thrombo-
prophylaxis. In a study of 261 critically ill patients (with or with-
out renal insufficiency) who received protocol-directed
thromboprophylaxis with unfractionated heparin 5,000 IU
twice daily, the ICU incidence of proximal DVT was 9.6%
(95% CI, 6.3 to 13.8) based on twice-weekly venous ultra-
sound screening that was the same screening approach [1] as
used in the present study. Furthermore, in the present study,
DVT occurred despite adequate levels of prophylactic antico-
agulation, based on peak anti-FXa levels of approximately 0.30
IU/ml. Although anti-FXa levels were missing for three of the
seven patients on the day DVT was diagnosed, previous anti-
FXa levels for each of these patients were within the range
observed with adequate anticoagulant prophylaxis regimens
(0.20–0.40 IU/ml). Taken together, these findings suggest
that ICU patients are a moderately high-risk group for develop-
ing DVT, and that anticoagulant thromboprophylaxis does not
completely mitigate the risk for DVT.
Our finding that an increase in the Acute Physiology and
Chronic Health Evaluation II score conferred an increased risk
for DVT is plausible given that this score reflects the presence
and severity of acute and chronic morbidities. Furthermore,
most critically ill patients are immobile, have central venous
catheters in place and undergo numerous other procedures,
all of which factors can increase the risk for DVT. Although we
did not find that conventional DVT risk factors such as throm-
bophilia or personal or family history of thrombosis conferred
an increased risk for DVT, this may reflect the low prevalence
of thrombophilia and a relatively underpowered regression
analysis.
Bleeding rates in ICU patients reported in the literature reflect
the objectives and case mix of individual studies. The 7% inci-
dence of major bleeding we observed reflects the exclusion of
patients who were bleeding or at high risk of bleeding at the
time of screening, as is typical for heparin thromboprophylaxis
studies. In a previous series of 19 medical–surgical ICU
patients without renal insufficiency receiving dalteparin
prophylaxis, only one patient had clinically important bleeding
[22]. On the other hand, in a study to estimate bleeding rates
in an unselected cohort of 100 consecutive ICU patients who
received unfractionated heparin 5,000 IU twice daily, the inci-
dence of major bleeding was 20% and most bleeding epi-
sodes were minor, recurrent and wound or procedure-related
[16]. In the present study, only 25 (5.6%) of the 480 bleeding
events were major.
We found that acquired coagulopathy (for example, increased
International Normalized Ratio) and concomitant use of drugs
affecting hemostasis (for example, prior aspirin use) were inde-
pendent risk factors for major bleeding, which is biologically
plausible and consistent with other studies assessing bleed-
ing risk factors in patients who are receiving anticoagulants.
As all patients received dalteparin, it is not possible to make
definitive inferences about the effect of LMWH use on bleed-
ing risk. We found, however, that a detectable trough antico-
agulant effect from dalteparin thromboprophylaxis, which may
be considered a surrogate marker for excessive anticoagula-
tion, was not associated with an increased risk for bleedingCritical Care    Vol 12 No 2    Cook et al.
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(odds ratio, 0.76; 95% CI, 0.15 to 3.81). The latter finding is
consistent with a systematic review of 11 studies of noncriti-
cally end-stage dialysis-dependent renal failure patients that
demonstrated no association between bleeding or extracor-
poreal circuit thrombosis and LMWH or unfractionated
heparin [23].
Our conclusions may be affected by the definitions of bleed-
ing. While there are multiple definitions of major and minor
bleeding in use, setting-specific reporting is necessary. Koreth
and colleagues identified over 16 published bleeding scales,
none of which were designed to capture clinically important
bleeding in critically ill patients [24]. Even among existing
Table 2
Risk factors for deep vein thrombosis
Putative risk factor Univariate analysis Multivariable analysis
Hazard ratio
(95% confidence interval)
P value Hazard ratio
(95% confidence interval)
P value
Baseline factors
Age (10-year increase) 0.98 (0.64 to 1.50) 0.91 - -
Acute Physiology and Chronic Health Evaluation II score
(10-point increase)
2.25 (1.03 to 4.91) 0.04 2.25 (1.03 to 4.91) 0.04
Surgical patient 1.96 (0.44 to 8.81) 0.38 - -
Baseline renal disease classification
(with reference to acute renal failure)
Acute on chronic 1.10 (0.21 to 5.78) 0.91
Chronic renal failurea --
Chronic hemodialysisa --
Personal or family history of venous thromboembolisma -- --
Known thrombophilic disorder 6.48 (0.73 to 57.88) 0.09 - -
Malignancy (current or in past 5 years)a -- --
Time-dependent factors
Exposure to continuous hemodialysisb 1.56 (0.30 to 8.08) 0.59 - -
Exposure to intermittent hemodialysisb 1.09 (0.21 to 5.67) 0.92 - -
Exposure to therapeutic-dose unfractionated heparinb -- --
Exposure to prophylactic-dose unfractionated heparinb 0.99 (0.12 to 8.37) 0.99 - -
Exposure to acetylsalicylic acidb 0.58 (0.11 to 2.97) 0.51 - -
International Normalized Ratio (0.5-unit increase) 1.54 (1.05 to 2.24) 0.03 - -
Partial thromboplastin time (10-unit increase) 1.08 (0.78 to 1.49) 0.67 - -
Platelet count (50-unit decrease) 1.09 (0.85 to 1.39) 0.49 - -
Red blood cell transfusiona 1.27 (0.28 to 5.71) 0.75 - -
Fresh frozen plasma transfusiona,b -- --
Platelet transfusiona,b -- --
Central venous catheter placementb -- --
Exposure to inotropes/vasopressorsb 0.80 (0.15 to 4.15) 0.79 - -
Exposure to mechanical ventilationb -- --
Peak anti-FXa levels
(most recent measurement prior to DVT diagnosis)c
0.04 (0.0 to 97.4) 0.43 - -
aNo patient with deep venous thrombosis (DVT) had this putative risk factor. bWithin 3 days prior to study enrollment. cThree out of seven patients 
with DVT did not have a peak anti-activated factor X (anti-FXa) level measured on the day of diagnosis of DVT; for this reason, the peak anti-FXa 
level was not included in the multivariable analysis.Available online http://ccforum.com/content/12/2/R32
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tools, no standardized definitions exist. A systematic review by
Raskob and colleagues identified 18 definitions of severe
bleeding among 62 studies of hip surgery thromboprophylaxis
[25]. In the present study, we used a clinically useful bleeding
measurement tool developed and validated in the ICU popula-
tion [16].
Limitations of the present study include the sample size.
Although this is the largest cohort study of ICU patients with
renal insufficiency receiving LMWH thromboprophylaxis, the
number of patients is a major determinant of the power of
regression analysis to identify risk factors for a prespecified
outcome. Previous studies involving critically ill patients [26] or
medical patients [27] were small and did not assess risk fac-
tors for adverse clinical outcomes using multivariate analysis.
Also, the importance of certain risk factors depends on the
prevalence of the risk factor in the population studied. We per-
formed screening venous ultrasound testing of the lower but
not the upper extremities, so we may have underestimated the
DVT rate overall. We did not identify central venous catheteri-
zation [28] as an independent predictor in our multivariate
regression, in part because almost all patients had central
venous catheters. Indeed, four of seven incident DVTs
observed in this study were catheter-related. Merrer and col-
leagues, however – in a randomized trial of femoral catheter
versus subclavian central venous catheter insertion – found
the catheter site to be an important determinant for DVT risk,
as femoral catheters conferred a higher risk for DVT [29].
Comparing DVT risk factor analyses across studies is method-
ologically challenging in this field, owing to differences in case
mix, consideration of different candidate risk factors, variable
approaches to the diagnosis of DVT (including cases compre-
hensively identified by screening versus a minority of DVTs
identified by physical examination), the different thrombo-
prophylaxis agents used, variable DVT location (proximal and/
or distal, lower-limb DVTs versus all DVTs), reliance on univar-
iate analyses rather than multivariate analyses, and typically
unreported events and exposures over the ICU course such
that risk factors include patients' baseline characteristics only.
Strengths of the present study include daily screening for con-
secutive eligible patients to be enrolled, thereby minimizing the
potential for selection bias. The ICU team and research coor-
Table 3
Risk factors for major bleeding
Putative risk factor Univariate analysis Multivariable analysis
Hazard ratio
(95% confidence interval)
P value Hazard ratio
(95% confidence interval)
P value
Baseline factors
Age (10-year increase) 0.82 (0.58 to 1.15) 0.25 - -
Acute Physiology and Chronic Health Evaluation II score
(10-point increase)
0.97 (0.49 to 1.93) 0.93 - -
Surgical patient 1.76 (0.50 to 6.26) 0.38 - -
Baseline renal disease classification
(with reference to acute renal failure)
Acute on chronic 0.92 (0.18 to 4.56) 0.91
Chronic renal failurea --
Chronic hemodialysis 3.59 (0.71 to 18.15) 0.12
Time-dependent factors
Exposure to continuous hemodialysisb 2.17 (0.55 to 8.51) 0.27 - -
Exposure to intermittent hemodialysisb 1.25 (0.32 to 4.85) 0.75 - -
Exposure to therapeutic-dose unfractionated heparinb 2.87 (0.59 to 13.97) 0.19 - -
Exposure to prophylactic-dose unfractionated heparinb 1.10 (0.14 to 8.80) 0.93 - -
Exposure to acetylsalicylic acidb 3.62 (0.93 to 14.11) 0.06 6.30 (1.35 to 29.35) 0.02
Detectable trough anti-activated factor X level (≥ 0.01 IU/ml) 0.76 (0.15 to 3.81) 0.74 - -
International Normalized Ratio (0.5-unit increase) 1.44 (0.95 to 2.17) 0.09 1.68 (1.07 to 2.66) 0.03
Partial thromboplastin time (10-unit increase) 1.13 (0.99 to 1.29) 0.06 - -
Platelet count (50-unit decrease) 1.19 (0.94 to 1.51) 0.16 - -
aNo patient with major bleeding had this putative risk factor. bWithin 3 days prior to study enrollment.Critical Care    Vol 12 No 2    Cook et al.
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dinators made comprehensive daily bleeding assessments
with a validated tool [16] and were blinded to the anti-FXa lev-
els. DVT was identified by twice-weekly screening venous
ultrasound, which has been protocolized in previous studies
[1,30] and has been shown to be reliable [12]. These design
features made biased interpretation of clinical outcomes
unlikely in this open-label study. We focused on independent
predictors of bleeding using multivariate analysis. Enrolment of
patients with a range of renal insufficiency including dialysis
dependence, from multiple centers, enhances the generaliza-
bility of our findings.
Conclusion
In summary, in the present multicenter observational study of
ICU patients with renal insufficiency, we observed that the inci-
dence of DVT and major bleeding is considerable. These
events, however, appear related to patient comorbidities
rather than an inadequate or excessive anticoagulant effect
from thromboprophylaxis with dalteparin.
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Key messages
￿  Critically ill patients with renal insufficiency are predis-
posed to both DVT and bleeding.
￿  In this multicenter study, ICU patients with estimated 
creatinine clearance <30 ml/min receiving dalteparin 
5,000 IU daily as thromboprophylaxis did not develop 
dalteparin bioaccumulation, as measured by twice-
weekly trough anti-FXa levels.
￿  DVT developed in 5.1% of patients. The only independ-
ent DVT risk factor was a high baseline Acute Physiol-
ogy and Chronic Health Evaluation II score (hazard ratio 
for 10-point increase, 2.25).
￿  Major bleeding developed in 7.2% of patients. The inde-
pendent risk factors for major bleeding were aspirin use 
(hazard ratio, 6.30) and a high international normalized 
ratio (hazard ratio for 0.5-unit increase, 1.68).
￿  Although DVT and major bleeding occurred during criti-
cal illness among patients with severe renal insuffi-
ciency, these events were not associated with an 
inadequate or an excessive dalteparin anticoagulant 
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